Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financi... (arterly Reports on Form 10-Qas filed wit...)

Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results

Date:2/5/2008

arterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Contact

SELECTED FINANCIAL DATA

(in thousands, except per share data)

(unaudited)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

Consolidated Statement of

Operations Data:

Revenues $2,767 $2,193 $9,098 $7,885

Operating expenses:

Research and development 7,904 10,057 25,559 21,527

General and administrative 2,470 1,942 8,310 7,087

Total operating expenses 10,374 11,999 33,869 28,614

Loss from operations (7,607) (9,806) (24,771) (20,729)

Interest and other income, net 935 858 3,291 2,865

Net loss $(6,672) $(8,948) $(21,480) $(17,864)

Basic and diluted net loss per

common share $(0.17) $(0.26) $(0.58) $(0.55)

Shares used in computing basic and

diluted net loss per common share 40,226 34,098 37,355 32,502

CONSOLIDATED CONDENSED BALANCE SHEET DATA

December 31, December 31,

2007 2006

Cash, cash equivalents, and

investments 81,412 53,975

Total assets 83,900 55,780

Total stockholders' equity 72,122 48,705

1

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
4. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
5. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
6. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
7. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
8. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
9. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System

Post Your Comments:

Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financi...(arterly Reports on Form 10-Qas filed wit...),Health